

Scientific Committee

- **Eva Martinez-Balibrea** - Chair of IMMUNO-model COST Action, Germans Trias i Pujol Research Institute (IGTP) and Catalan Oncology Institute (ICO), Spain
- **Vitor Gaspar** - University of Aveiro, Portugal
- **Ana Mitrovic** - Jožef Stefan Institute, Slovenia
- **Hatim Boughanem** - Cordoba Institute for Biomedical Research (FIBICO), Spain

Local Organising Committee

- **Eva Martinez-Balibrea** - Chair of IMMUNO-model COST Action, Germans Trias i Pujol Research Institute (IGTP) and Catalan Oncology Institute (ICO), Spain
- **Arola Fortian** - Germans Trias i Pujol Research Institute (IGTP), Spain
- **Beatriz Gonzalez** - Germans Trias i Pujol Research Institute (IGTP), Spain
- **Sara Bystrup** - Germans Trias i Pujol Research Institute (IGTP), Spain
- **Ferran Grau** - Germans Trias i Pujol Research Institute (IGTP), Spain
- **Sergio Alonso** - Germans Trias i Pujol Research Institute (IGTP), Spain
- **Jordi Barretina** - General Director, Germans Trias i Pujol Research Institute (IGTP) and Catalan Oncology Institute (ICO), Spain

How to get to CosmoCaixa



[C. de Isaac Newton, 26, 08022 Barcelona](#)



Bus lines

H2, H4, V17, V15



Train

Line L7 - Av. Tibidabo station



IMMUNO-model Website



www.immuno-model.eu



in



X

IMMUNO-model Symposium

Modelling Immunotherapy in 3D: Bridging the Gap to the Clinic

9th February 2026

CosmoCaixa

TAU meeting room

Barcelona, Spain




Image credits:
Cancer Genetics and Epigenetics (CGE), IGTP




Funded by
the European Union

Supported by:




Organised by:



IMMUNO-model
Modelling immunotherapy response
and toxicity in cancer



Modelling Immunotherapy in 3D: Bridging the Gap to the Clinic



IMMUNO-model
Modelling immunotherapy response
and toxicity in cancer

9th February 2026
CosmoCaixa
Barcelona, Spain

8:30 – 9:00

Registration

9:00 – 9:15

Welcome

Eva Martinez-Balibrea, Chair of IMMUNO-model COST Action (Badalona, ES);
Jordi Barretina, IGTP Director (Badalona, ES).

Session I

Chairs: Sara Bystrup, Germans Trias i Pujol Research Institute (IGTP) (Badalona, ES) & Vitor Gaspar, University of Aveiro (Aveiro, PT).

9:15 – 9:35

Strength through diversity: Patient-derived organoids to dissect the heterogeneity of immune evasion in cancer

Krijn Dijkstra, The Netherlands Cancer Institute (Amsterdam, NL)

9:45 – 10:05

Immuno-Epithelioids: Preclinical in vitro modelling of immune-epithelial dynamics for immunotherapy development

David Fernandez-Antorán, IIS-Aragon (Zaragoza, ES) and The Gurdon Institute, University of Cambridge (Cambridge, UK)

10:15 – 11:00

Coffee break

11:00 – 11:20

Modelling Immunotherapy-Associated Toxicities in Human Autologous Immuno-Organoids

Lauriane Cabon, Roche Institute of Human Biology (Basel, CH)

Session II

Chairs: Arola Fortian, IGTP (Badalona, ES) & Ferran Grau, IGTP (Badalona, ES).

11:30 – 11:50

Multi-cellular models of the ovarian cancer microenvironment to study immunotherapies

Frances Balkwill, Centre for Tumour Microenvironment; Barts Cancer Institute, Queen Mary University of London (London, UK)

12:00 – 12:20

Tumor-on-Chip as a personalised immunocompetent platform for rapid drug testing

Maria Carla Parrini, Institut Curie - Inserm U1339 - CNRS UMR3666 (Paris, FR)

12:30 – 12:50

Modelling antitumour immune responses in human tumours to decode ICB clinical outcome

Mercedes Machuca-Ostos, The Netherlands Cancer Institute; Oncode Institute (Amsterdam, NL)

13:00 – 14:00

Lunch break

Featured Talk

14:00 – 14:30

Modelling human tumour and tissue microenvironments using organoids

Calvin J Kuo, Stanford University School of Medicine (Palo Alto, USA)

Session III

Chairs: Hatim Boughanem, Cordoba Institute for Biomedical Research (FIBICO) (Cordoba, ES) & Beatriz Gonzalez, IGTP (Badalona, ES).

14:40 – 14:50

A Scalable 3D Ex Vivo Platform for Long-Term Immuno-Oncology Drug Screening in NSCLC.

Jens Kelm, CSO, PreComb AG, (Hombrechtikon, CH)

15:00 – 15:10

TBC - Industry Talk

Short Talks

15:20 – 15:35

Short Talk 1. *Targeting HIF2 α and PD-1 axes in patient-derived models of renal cancer*

Maitane Márquez López, Biogipuzkoa Health Research Institute (San Sebastian, ES)

15:40 – 15:55

Short Talk 2. *Establishing an Ovarian Cancer Patient AVATAR Using Malignant Ascites to Study Immunotherapy Approaches*

Melissa Shahriari, University Medical Center Hamburg-Eppendorf (Hamburg, DE)

16:00 – 16:15

Short Talk 3. *Microfluidic modelling of CAR-T cell trafficking and cytotoxic activity in solid tumours*

Jack Zhang-Zhou, University of Zaragoza (Zaragoza, ES)

16:20 – 16:35

Short Talk 4. *Exploring the Potential of BCG-Primed Anti-Tumour NK Cell Immunotherapy in 3D Preclinical Systems*

Maria-Jose Felgueres, Spanish National Centre for Biotechnology (CNB-CSIC), (Madrid, ES)

16:40 – 17:20

Round Table

Chairs: Eva Martinez-Balibrea, IGTP and Catalan Oncology Institute (ICO) (Barcelona, ES) & Sergio Alonso, IGTP (Badalona, ES).

17:20 – 17:30

Closing remarks

Eva Martinez-Balibrea, IGTP and ICO (Barcelona, ES).